Ind-Swift Laboratories Limited announces a new order win

The exact unutilized balance was ₹0.00 Cr as of 30 September 2026. The Q2 FY27 report states that the ₹3.77 Cr opening balance was fully utilized during the quarter, making this the final Monitoring Agency Report. ^[1] The summary table also records total unutilized proceeds of ₹0.00 Cr. ^[2]

Interpretation: the proceeds were fully deployed in line with the stated objects; there was no residual issue cash awaiting deployment into capex or debt reduction. However, the company raised only ₹255.61 Cr against the original ₹314.60 Cr plan—a ₹58.99 Cr shortfall caused by 65 lakh warrants not being exercised. ^[3] Management stated that this shortfall was being met through internal accruals while expansion and subsidiary investment continued as planned. ^[5]

Debt reduction caveat: the reproduced original-object schedule does not show a separate debt-reduction allocation; it lists expansion, subsidiary investment, working capital and general corporate purposes totaling ₹314.60 Cr. ^[3] Therefore, the Q2 report supports full utilization against the disclosed objects and ongoing capex execution, but does not establish that any preferential-issue proceeds were earmarked for or used for debt reduction.

The Q2 FY27 filing does not support any quantified retirement of high-cost debt using the preferential issue proceeds. The reported ₹255.61 Cr raised was fully utilized, but the disclosed uses were business expansion, subsidiary investment, working capital and general corporate purposes—not debt repayment ^[4]. The ₹3.77 Cr utilized during Q2 FY27 was specifically for building construction and machinery advances ^[4].

Quantifiable leverage and coverage position

• Interest coverage: 39.89x in Q2 FY27 versus 57.87x in Q1 FY27, a decline of 17.98x, or 31.1%, derived from the reported ratios ^{[6] [7]}. This cannot be attributed to interest savings from preferential proceeds because no debt-retirement amount or avoided interest expense is reported.
• Debt-to-equity: remained at 0.01x in both Q1 and Q2 FY27 ^{[8] [9]}.
• Gross debt: increased from ₹17.91 Cr to ₹19.56 Cr, a derived increase of ₹1.65 Cr, rather than showing a reduction ^{[10] [11]}.
• Net debt-to-equity: improved from negative 0.30x to negative 0.22x, but this reflects the reported balance-sheet position and does not establish that preferential proceeds were used to retire borrowings ^{[12] [13]}.

Conclusion: the quantum of high-cost debt retired using the preferential issue proceeds could not be confirmed from the Q2 FY27 utilization filing. Accordingly, the filing does not provide a basis to quantify an interest-cost saving or a debt-to-equity reduction attributable to that action; the reported Q2 profile instead shows very low leverage at 0.01x, with gross debt modestly higher sequentially.

Verdict: The Q2 FY27 report shows front-loaded deployment of the preferential-issue proceeds, but only a modest incremental draw in Q2: ₹251.84 Cr, or 98.5% of the ₹255.61 Cr actually raised, had already been utilized at the start of the quarter; Q2 deployment was ₹3.77 Cr, equivalent to 1.5% of proceeds. ^[2] This cannot be compared reliably with a historical capex “cycle” because the cited materials provide no comparable FY25–FY26 deployment series; FY26 total capex of ₹87.72 Cr is only a single company-wide datapoint and is not directly comparable with issue-proceeds utilization. ^[14]

Deployment pace versus the stated plan

Does utilization indicate a timeline deviation?

Not formally, but it does leave execution timing open. The offer-document timeline set business expansion for completion by 31 December 2027 and subsidiary investment by 31 December 2026. Both were still marked “not yet completed” in the Q2 FY27 report, although the Board stated that the objects were being implemented as planned and that the shortfall in fundraising would be met through internal accruals. ^[5]

The Monitoring Agency also recorded no deviation from the objects and no major deviation from earlier reports. ^[15] However, this should not be read as proof that the physical expansion schedule is fully on track: the report measures fund utilization, not installed capacity, commissioning, production ramp-up, or efficiency gains.

There is one execution complication. Land acquired in January 2025 for a formulation facility was subsequently found unsuitable and sold in August 2026; the company redirected the sale advance toward capex. ^{[16] [17]} This suggests a change in project implementation, but the report does not classify it as formal schedule slippage.

Conclusion: utilization is complete for the actual funds raised, but the original funding plan was 18.7% larger and the expansion and subsidiary objects were not yet complete. Therefore, the report supports no formally reported deviation from the stated objects, while the lower funding pool, land-related project reset, and incomplete milestones leave the ultimate capacity-expansion timeline less certain. A separate timeline for operational-efficiency projects could not be confirmed; the report specifically identifies expansion construction and machinery procurement, not a distinct efficiency-project schedule.